Urine Test Accurate for Active Surveillance Monitoring of Prostate Cancer

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 20, 2026.

via HealthDay

TUESDAY, May 19, 2026 -- Noninvasive monitoring of low-grade prostate cancer with a urinary biomarker test could reduce the need for biopsies and serial imaging, according to a study published online April 28 in The Journal of Urology.

Jeffrey J. Tosoian, M.D., M.P.H., from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues developed and validated a nondigital rectal examination urine test to inform whether biopsy is necessary in patients undergoing active surveillance (AS). Diagnostic performance and clinical consequences of urinary testing to determine the need for biopsy were compared to multiparametric magnetic resonance imaging (mpMRI) in 330 patients with grade group (GG) 1 cancer scheduled for AS biopsy.

The researchers found that on biopsy, 9.4 percent of patients upgraded to GG ≥3 and 37 percent to GG ≥2. The MyProstateScore 2.0-Active Surveillance (MPS2-AS) biomarker model provided a higher area under the curve than mpMRI for upgrading to both GG ≥3 (0.82 versus 0.73) and GG ≥2 (0.74 versus 0.64). Prebiopsy MPS2-AS would have avoided nearly two-thirds (64 percent) of unnecessary biopsies while failing to detect only 3.2 percent of GG ≥3 upgrades. Use of Prostate Imaging Reporting and Data System ≥3 would have failed to detect 18 percent of GG ≥3 upgrades and avoided 50 percent of unnecessary biopsies. MPS2-AS performance was consistent across clinically pertinent subgroups, including confirmatory and surveillance biopsy and Black and non-Black patients.

"For patients undergoing monitoring of low-grade prostate cancer, these findings suggest that use of the urine test can reduce the need for invasive biopsies without compromising prompt detection of higher-grade cancers that require treatment," Tosoian said in a statement.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-20 09:50

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords